Do you have Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)?
Treatment is currently based on opening the small blood vessels in the lungs to ease the heart’s work of pumping blood to the lungs.
What’s New in Research?
B cells are immune cells that are thought to attack normal lung cells and that may lead to SSc-PAH. Rituximab eliminates B cells for a few months and is an FDA-approved immunosuppressive drug to treat other diseases. This clinical trial is researching if Rituximab treatment affects your SSc-PAH.
Who is Eligible for This Study?
If you are currently being treated with medications for PAH and are 18-75 years old, you may be eligible to participate in this clinical trial! You can learn more about ASC01 study (trial ID NCT01086540) by visiting clinicaltrials.gov.